Iron-chelation therapy with oral deferiprone in patients with thalassemia major

New England Journal of Medicine

Volumn 332, Issue 14, 1995, Pages 918-922

  Olivieri, Nancy F ^a   Brittenham, Gary M ^a   Matsui, Doreen ^a   Berkovitch, Matitiahu ^a   Blendis, Laurence M ^a   Cameron, Ross G ^a   Mcclelland, Robert A ^a   Liu, Peter P ^a   Templeton, Douglas M ^a   Koren, Gideon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER LEVEL; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA MAJOR;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; COMPARATIVE STUDY; DRUG MONITORING; FERRITIN; HUMAN; IRON; IRON CHELATING AGENTS; LIVER; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; PYRIDONES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028898064     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199504063321404     Document Type: Article

References (37)

1. Cohen A.R. Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1987; 1.: 521-544
2. Engle MA, Erlandson M, Smith CH Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964; 30.: 698-705
3. Brittenham GM, Griffith PM, Nienhuis AW, Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331.: 567-573
4. Olivieri NF, Nathan DG, MacMillan JH, Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331.: 574-578
5. Porter JB, Huehns ER The toxic effects of desferrioxamine. Baillieres Clin Haematol 1989; 2.: 459-474
6. Kontoghiorghes GJ, Aldouri MA, Sheppard LN, Hoffbrand AV 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987; 1.: 1294-1295
7. Olivieri NF, Koren G, St Louis P, Freedman MH, McClelland RA, Templeton DM Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. Semin Hematol 1990; 27.: 101-104
8. Vreugdenhil G, Swaak AJ, De Jeu-Jaspers C, Van Eijk HG Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) and transferrin and possible antianemic effects of L1 in rheumatoid arthritis. Ann Rheum Dis 1990; 49.: 956-957
9. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990; 76.: 295-300
10. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy AR, L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol 1990; 76.: 550-553
11. Olivieri NF, Koren G, Hermann C, Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990; 336.: 1275-1279
12. Matsui D, Klein J, Hermann C, Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991; 50.: 294-298
13. Olivieri NF, Koren G, Matsui D, Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992; 79.: 2741-2748
14. al-Refaie RN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992; 80.: 593-599
15. Agarwal MB, Gupte SS, Viswanathan C, Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia.: Indian trial. Br J Haematol 1992; 82.: 460-466
16. Collins AF, Fassos FF, Stobie SS, Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994; 83.: 2329-2333
17. Hoffbrand AV, Bartlett AN, Veys PP, O'Connor NTJ, Kontoghiorghes GJ Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet 1989; 2.: 457-457
18. Olivieri NF, Sher GD, MacKinnon JA, The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chelating agent L1. Blood 1994; 84.: Suppl 1.: 363a-363a
19. Olivieri NF, Buncic JR, Chew E, Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314.: 869-873
20. Olivieri NF, Koren G, Harris J, Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992; 14.: 48-56
21. Kontoghiorghes GJ, Sheppard LN Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones. Inorg Chim Acta 1987; 136.: L11-L11
22. Brittenham GM, Farrell DE, Harris JW, Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307.: 1671-1675
23. Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER, Hider RC Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 1990; 76.: 2389-2396
24. Porter JB, Hoyes KP, Abeysinghe RD, Brooks PN, Huehns ER, Hider RC Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice. Blood 1991; 78.: 2727-2734
25. Bergeron RJ, Streiff RR, Weigand J, Luchetta G, Creary EA, Peter HH A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood 1992; 79.: 1882-1890
26. Biesemeier JA, Laveglia J. 14-Day oral toxicity study in dogs with 1,2-dimethyl-3-hydroxypyrid-4-one (DMHP, L1). Waverly, N.Y.: Food and Drug Research Laboratories, 1991.
27. Schnebli HP, ed. Final report.: preclinical evaluation of CGP 37 391 (L1). Biology report ERS 62/93. Basel, Switzerland.: Ciba-Geigy, 1993.:30.
28. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261.: 3273-3277 [Erratum, JAMA 1989;262.:1472.]
29. Berkovitch M, Laxer RM, Inman R, Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994; 343.: 1471-1472
30. Mehta J, Singhal S, Chablani A, Revankar R, Walvalkar A L1-induced systemic lupus erythematosus. Indian J Hematol Blood Transfus 1991; 9.: 33-37
31. Barry M, Flynn D, Letsky E, Risdon RA Long-term chelation therapy in thalassaemia major.: effect on liver iron concentration, liver histology, and clinical progress. BMJ 1974; 2.: 16-20
32. Cohen AR, Martin M, Schwartz E Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984; 58.: 369-373
33. Wolfe LC, Olivieri NF, Sallan DL, Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312.: 1600-1603
34. Bronspiegel-Weintrob N, Olivieri NF, Tyler BJ, Andrews DF, Freedman MH, Holland FJ Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990; 323.: 713-719
35. Zurlo MG, De Stefano P, Borgna-Pignatti C, Survival and causes of death in thalassemia major. Lancet 1989; 2.: 27-30
36. Fosburg MT, Nathan DG Treatment of Cooley's anemia. Blood 1990; 76.: 435-444
37. Brittenham GM, Cohen AR, McLaren C, Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42.: 81-85